A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.
As Global Head of Oncology for IQVIA Biotech, Gerhard du Toit manages all aspects of oncology clinical trials, optimising strategies and enhancing delivery from early to late phases.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
